News

- Dyno receives $18 million upfront and is eligible for milestone and royalty payments potentially exceeding $1.6 billion - TOKYO and CAMBRIDGE, Mass., Dec. 2, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Dyno Therapeutics, Inc. (President and CEO: Eric Kelsic, Ph.D., “Dyno”) today announced an option and license agreement was signed on November...

• Four AML oral presentations are among highest number of Astellas-sponsored ASH abstracts to date • Full results of Phase 3 LACEWING, COMMODORE trials will be presented • Oral presentation explores potential sickle cell disease treatment pathway TOKYO, Dec. 1, 2021 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced the presentation of new...

Astellas publish its annual report as an integrated report to enable deeper stakeholder understanding of Astellas' efforts to continuously create value for sustainable growth. Annual Report 2021 is now available at the following link: https://www.astellas.com/system/files/astellas_ar2021_en_20211126.pdf In order to check the latest information on each item of the annual report, please visit the...

New pediatric formulation of Praziquantel, which Astellas Pharma Inc. (“Astellas”) provided its formulation technology and has been developed under the initiative of Merck together with its consortium partners, has now been completed its pivotal Phase 3 trial. The favorable results of this clinical trial allow the program to progress towards regulatory file submission to the European Medicines...